CD 44 v 6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma Monica Casucci, Benedetta Nicolis di Robilant, Laura Falcone, Barbara Camisa, Margherita Norelli, Pietro Genovese, Bernhard Gentner, Fabiana Gullotta, Maurilio Ponzoni, Massimo Bernardi, Magda Marcatti, Aurore Saudemont, Claudio Bordignon, Barbara Savoldo, Fabio Ciceri, Luigi Naldini, Gianpietro Dotti, Chiara Bonini, and Attilio Bondanza

[1]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[2]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[3]  Angel F. Lopez,et al.  Targeting of acute myeloid leukaemia by cytokine‐induced killer cells redirected with a novel CD123‐specific chimeric antigen receptor , 2013, British journal of haematology.

[4]  C. Eaves,et al.  Enhanced normal short-term human myelopoiesis in mice engineered to express human-specific myeloid growth factors. , 2013, Blood.

[5]  S. Bicciato,et al.  IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. , 2013, Blood.

[6]  H. Fine,et al.  Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. , 2012, Human gene therapy.

[7]  Kecheng Xu,et al.  Detection and Clinical Significance of CD44v6 and Integrin-β1 in Pancreatic Cancer Patients using a Triplex Real-Time RT-PCR Assay , 2012, Applied Biochemistry and Biotechnology.

[8]  Jinjuan Wang,et al.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.

[9]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[10]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[11]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[12]  Adrian P Gee,et al.  Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.

[13]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[14]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[15]  C. Bordignon,et al.  IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. , 2011, Blood.

[16]  Hao Liu,et al.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.

[17]  M. Zöller.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? , 2011, Nature Reviews Cancer.

[18]  Thomas M. Schmitt,et al.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. , 2010, Blood.

[19]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[20]  Alessandra Biffi,et al.  Identification of Hematopoietic Stem Cell–Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy , 2010, Science Translational Medicine.

[21]  S. Rosenberg,et al.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. , 2010, The Journal of clinical investigation.

[22]  T. Schumacher,et al.  Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy , 2010, Nature Medicine.

[23]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  M. Sadelain,et al.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  R. Grossman,et al.  HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors , 2010, Clinical Cancer Research.

[26]  S. Rosenberg,et al.  A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity1 , 2009, The Journal of Immunology.

[27]  A. Ganser,et al.  Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. , 2009, The Lancet. Oncology.

[28]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[29]  T. Nagasawa,et al.  IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. , 2009, Blood.

[30]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[31]  H. Heslop,et al.  Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. , 2007, Blood.

[32]  R. Fanin,et al.  A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.

[33]  R. A. Etten,et al.  Requirement for CD44 in homing and engraftment of BCR-ABL–expressing leukemic stem cells , 2006, Nature Medicine.

[34]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[35]  Alexander Staab,et al.  A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus , 2006, Clinical Cancer Research.

[36]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[37]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[38]  P. Sharp,et al.  A positive feedback loop couples Ras activation and CD44 alternative splicing. , 2006, Genes & development.

[39]  C. Bordignon,et al.  Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. , 2005, Blood.

[40]  H. Heslop,et al.  An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.

[41]  L. Naldini,et al.  Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters , 2005, Nature Biotechnology.

[42]  E. Thiel,et al.  Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. , 2003, Cancer research.

[43]  W. Oyen,et al.  Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  H. Kluin-Nelemans,et al.  A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. , 1998, Blood.

[45]  R. Handgretinger,et al.  Expression of CD44 isoforms by highly enriched CD34-positive cells in cord blood, bone marrow and leukaphereses , 1997, Bone Marrow Transplantation.

[46]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[47]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.

[49]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[50]  เอกรัฐ รัฐฤทธิ์ธำรง.  Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation , 2009 .

[51]  H. Döhner,et al.  CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. , 2005, Haematologica.

[52]  P. Herrlich,et al.  CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.